Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Summary

This phase II trial studies how well giving bicalutamide with or without Akt inhibitor MK2206 works in treating patients with previously treated prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether bicalutamide is more effective with or without Akt inhibitor MK2206 in treating prostate cancer.

Timeline

Start

2011-03-17

Primary completion

2018-07-17

Completion

2026-05-26

Publications

• Ferrari AC, Chen YH, Rodriguez R, Hudes GR, Antonarakis ES, Hahn NM, Ma H, Plimack ER, Mayer T, Carthon BC, Liu G, Carducci MA, DiPaola R. Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809). Prostate. 2026 May;86(6):697-709. doi: 10.1002/pros.70125. Epub 2026 Jan 29.

Drugs

Indications